Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4

Author(s): Sayed Ahmed, Essam Hassan, Ahmed Gomaa, Gamal Esamat, Ahmed Ramadan, Manar Ahmed, Aya Elsayed and Engy A. Wahsh*

Volume 18, Issue 2, 2023

Published on: 05 August, 2022

Page: [207 - 213] Pages: 7

DOI: 10.2174/1574886317666220510184749

Price: $65

Abstract

Background: Chronic infection with HCV is progressive worldwide health problem and the core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 represents the most common threat to transplantation of the liver in Egypt. New interferon-free regimens have been started consuming direct-acting antiviral oral tablets for HCV cure.

Objectives: In the current study, comparing the safety and efficacy of DAAs combination regimens including sofosbuvir with daclatasvir or sofosbuvir with simeprevir plus ribavirin for naïve cirrhotic Egyptian patients infected with HCV-G4 was our main goal.

Methods: We recruited 150 naïve cirrhotic HCV patients from the Tropical patients’ clinic at Fayoum General Hospital. They were classified randomly into two groups, group one (n=75 patients) were administrated Sofosbuvir plus simeprevir (400 mg and 150 mg once daily respectively ) for twelve weeks, and group two (n=75 patients) were administrated Sofosbuvir plus Daclatasvir (400 mg and 60 mg once daily respectively) with ribavirin (1-1.2 gm daily weight-based) for twelve weeks. Clinical follow-up, laboratory investigations, and viral PCR were measured to detect treatment efficacy, safety, and any adverse events.

Results: Sustained virological response rates (SVR12) were 92%and 90.7% in the first and second groups, respectively. The major unfavorable events were fatigue, arthralgia, and weight loss without statistically meaningful differences between study groups. However, anemia and headache were significantly widespread in the second group (P=0.0161 and 0.0495, respectively). We observed four patients with photosensitivity in group I and not observed in the second group.

Conclusion: The current study revealed that DAAs are safe and effective in the cure of naïve cirrhotic patients chronically infected by HCV-G4 with better results in those treated with sofosbuvir plus simeprevir regimen.

Keywords: Hepatitis C virus, sofosbuvir, daclatasvir, simeprevir, ribavirin, genotype-4.

« Previous Next »
[1]
Ahmed M, Mansey AE, Wahsh EA, Gomaa AA, Rabea HM. Efficacy and safety of ombitasvir plus paritaprevir, ritonavir and ribavirin in non-cirrhotic treatment-naïve and treatment-experienced egyptians with chronic HCV genotype-4 infection. Curr Med Sci 2021; 41(3): 581-6.
[http://dx.doi.org/10.1007/s11596-021-2363-9] [PMID: 34047942]
[2]
Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: Implications for future policy on prevention and treatment. Liver Int 2017; 37(1): 45-53.
[http://dx.doi.org/10.1111/liv.13186] [PMID: 27275625]
[3]
Wahsh E, Hussein A, Gomaa A, Baraka M, Abead M. Safety and efficacy of combination therapy (simeprevir/sofosbuvir) in the treatment of chronic HCV genotype IV patients. Med Sci (Turkey) 2018; 7(1): 122-6.
[http://dx.doi.org/10.5455/medscience.2017.06.8730]
[4]
Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: Focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6: 37-45.
[http://dx.doi.org/10.2147/DHPS.S43304] [PMID: 24729731]
[5]
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(1) (Suppl.): S45-57.
[http://dx.doi.org/10.1016/j.jhep.2014.07.027] [PMID: 25086286]
[6]
Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. J Transl Int Med 2017; 5(1): 8-17.
[http://dx.doi.org/10.1515/jtim-2017-0007] [PMID: 28680834]
[7]
Koff RS. Review article: The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39(5): 478-87.
[http://dx.doi.org/10.1111/apt.12601] [PMID: 24387618]
[8]
OLYSIO [Package Insert]. Titusville, NJ: Janssen Therapeutics 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205123s012lbl.pdf Accessed on Feb 17, 2017.
[9]
Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370(16): 1560-1.
[http://dx.doi.org/10.1056/NEJMc1401726] [PMID: 24738674]
[10]
Nelson DR, Cooper JN, Lalezari JP, et al. ALLY-3 study team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61(4): 1127-35.
[http://dx.doi.org/10.1002/hep.27726] [PMID: 25614962]
[11]
Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Effects of mild and moderate renal impairment on ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin pharmacokinetics in patients with chronic HCV infection. Eur J Drug Metab Pharmacokinet 2017; 42(2): 333-9.
[http://dx.doi.org/10.1007/s13318-016-0341-6] [PMID: 27165046]
[12]
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384(9956): 1756-65.
[http://dx.doi.org/10.1016/S0140-6736(14)61036-9] [PMID: 25078309]
[13]
Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64(2): 360-9.
[http://dx.doi.org/10.1002/hep.28422] [PMID: 26704148]
[14]
Nelson DR, Cooper JN, Lalezari JP, et al. All oral 12 week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: Ally-3 phase III study. Hepatology 2015; 61: 1127e35.
[15]
Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014; 59(1): 318-27.
[http://dx.doi.org/10.1002/hep.26744] [PMID: 24115039]
[16]
Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63(3): 581-5.
[http://dx.doi.org/10.1016/j.jhep.2015.04.023] [PMID: 25937436]
[17]
Manns M, Gane EJ, Willems BE, et al. The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in> 1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis. J Hepatol 2017; 1(66): S722-3.
[http://dx.doi.org/10.1016/S0168-8278(17)31930-X]
[18]
Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016; 64(4): 1049-56.
[http://dx.doi.org/10.1002/hep.28706] [PMID: 27351341]
[19]
Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): A multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016; 1(1): 36-44.
[http://dx.doi.org/10.1016/S2468-1253(16)30002-4] [PMID: 28404110]
[20]
Jacobson IM, Lawitz E, Kwo PY, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: An integrated analysis. Gastroenterology 2017; 152(6): 1372-1382.e2.
[http://dx.doi.org/10.1053/j.gastro.2017.01.050] [PMID: 28193518]
[21]
Wahsh E A, Hussein A K, Gomaa A A, Baraka M A, Abead A D. Real life Egyptian experience of daclatasvir plus sofosbuvir with Ribavirin in Naïve difficult to treat HCV patients. Infect Disord Drug Targets 2020; 20(1): 43-8.
[22]
Pott-Junior H, Bricks G, Grandi G, Figueiredo Senise J, Castelo Filho A. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: A randomized clinical trial. Clin Microbiol Infect 2019; 25(3): 365-71.
[http://dx.doi.org/10.1016/j.cmi.2018.06.007] [PMID: 29906601]
[23]
Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: A real-life experience. Arch Virol 2020; 165(7): 1633-9.
[http://dx.doi.org/10.1007/s00705-020-04639-x] [PMID: 32356185]
[24]
Arends JE, Kracht PAM, Hoepelman AIM. Performance of Hepatitis C Virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016; 22(10): 846-52.
[http://dx.doi.org/10.1016/j.cmi.2016.05.027] [PMID: 27297320]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy